Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)

June 18, 2026

Lorusso et al. • 2026 • ESMO Gyn

SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies

May 30, 2026

Hamid et al. • 2026 • ASCO

Overall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer

May 29, 2026

Gilbert et al. • 2026 • ASCO

Real-World Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)

April 13, 2026

Coleman et al. • 2026 • SGO

BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers

April 13, 2026

Lorusso et al. • 2026 • SGO